Please login to the form below

Not currently logged in
Email:
Password:

David Holliday joins Octapharma USA as VP commercial development

Moves from Baxter Bioscience to take up senior sales and marketing role in the US

David Holliday - Octapharma USAOctapharma USA has appointed Baxter Bioscience's former VP of global marketing operations and haemophilia as its new VP of commercial development.

David Holliday will lead all US product marketing, sales and commercial activities at Octapharma, along with co-ordinating its global portfolio development initiatives.

The company is the US affiliate of Swiss-headquartered Octapharma AG, which develops and manufactures human protein products.

Holliday spent eight years at Baxter, gaining US and international experience in management, sales, marketing and business development, and was responsible for several successful product launches.

Prior to his time at Baxter, he held leadership positions at both Novartis and Ciba-Geigy Pharmaceuticals.

“We are very excited to have David Holliday, a true global leader in our industry, join our senior management team,” said Octapharma's USA president, Flemming Nielsen.

“He joins Octapharma USA at an extremely important time for our company as our product portfolio in the US will be increasing significantly in the next year and we expect David will be integral to our growth.”

26th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics